The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, yet its position within the broader market now raises questions about future gains. Copycat versions are eroding patent protection , leading to concerns that investing in companies closely tied to Viagra's former position could be a speculative strate